HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MD
Pediatrix Medical Group, Inc.
MD's fundamentals are mixed, but it looks expensive: trading at 17x earnings, above its usual 13x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Healthy |
MD's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $19.61 | -38% |
| Fair | 13x | $23.57 | -25% |
| Forward | 13x | $31.40 | — |
| Current | 17x | $31.40 | — |
| Expensive | 19x | $34.33 | +9.3% |
Historical ranges are pointers, not guarantees.
MD's PE is in its expensive range at 17x. If earnings grow as analysts expect, today's price would be 13x next year's earnings, in its fair range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect MD's earnings to grow and its profitability to improve, with its revenue holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
MD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.45 | +33% |
| Q3 2026 | $1.84 | -3.7% |
| Q2 2026 | $2.09 | +61% |
| Q1 2026 | $2.06 | +$3.06 |
| Q4 2025 | $1.94 | +$3.13 |
| Q3 2025 | $1.91 | +$4.97 |
| Q2 2025 | $1.30 | +$4.33 |
| Q1 2025 | -$1.00 | -$0.15 |
| Q4 2024 | -$1.19 | -$0.46 |
MD has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
MD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $501.4M | +1.7% |
| Q2 2026 | $487.8M | +4% |
| Q1 2026 | $476.2M | +3.9% |
| Q4 2025 | $493.8M | -1.7% |
| Q3 2025 | $492.9M | -3.6% |
| Q2 2025 | $468.8M | -7% |
| Q1 2025 | $458.4M | -7.4% |
| Q4 2024 | $502.4M | +1.2% |
MD's revenue fell from its 2019 peak and has held roughly level since: $501M last quarter, up 1.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | -0.8 points |
| Q2 2026 | 12% | -1.1 points |
| Q1 2026 | 8.8% | +1.8 points |
| Q4 2025 | 9.9% | +2.1 points |
| Q3 2025 | 14% | +7.2 points |
| Q2 2025 | 13% | +44 points |
| Q1 2025 | 7% | +3.8 points |
| Q4 2024 | 7.8% | +30 points |
MD has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MD on cash flow, with more consistent year-over-year improvement.
MD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $112.9M | -14% |
| Q2 2026 | $123.9M | -6.6% |
| Q1 2026 | -$136.1M | -$15.3M |
| Q4 2025 | $108.8M | -16% |
| Q3 2025 | $131.9M | +54% |
| Q2 2025 | $132.7M | +33% |
| Q1 2025 | -$120.8M | +$9.8M |
| Q4 2024 | $129.6M | +115% |
MD still generates free cash flow, though less than at its 2020 peak: $210M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.1% | -1.7M shares |
| 1 year | -6.9% | -5.9M shares |
| 3 years | -3.9% | -3.2M shares |
| 5 years | -7.4% | -6.4M shares |
| Available history | -4.3% | -3.6M shares |
MD has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $83M |
| Q2 2026 | $42.7M |
| Q1 2026 | $21.5M |
| Q4 2025 | $64M |
| Q3 2025 | $20.9M |
| Q2 2025 | $209,000 |
| Q1 2025 | $1.6M |
| Q4 2024 | $643,000 |
MD spent $211M buying back its own shares over the past year, about nine times what it spent the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.1x | Healthy |
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.6x | Healthy |
| Q4 2025 | 1.0x | Very low |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 2.0x | Moderate |
| Q1 2024 | 2.9x | Moderate |
| Q4 2023 | 12.9x | High |
MD's net debt is about 1.1 years of its operating earnings (EBITDA), about the same as a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 77.7 | Overbought |
| Stochastic | 80.5 | Overbought |
MD's weekly RSI is 78 (overbought) and its Stochastic is 81 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MD PE vs Healthcare Sector
| Metric | MD | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 34% below |
| PE % | 72 | 29 | 43 pts above |
MD is trading at 17x earnings, a 34% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.5 | 10% above |
| 20 week MA | $27.3 | 15% above |
| 50 week MA | $24.0 | 31% above |
| 100 week MA | $19.6 | 60% above |
| 200 week MA | $15.6 | 101% above |
MD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
MD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $27.2 | $23.9 | -12% |
| 2021 | $23.9 | $27.6 | +15% |
| 2022 | $27.6 | $14.9 | -46% |
| 2023 | $14.9 | $9.30 | -38% |
| 2024 | $9.30 | $13.5 | +45% |
| 2025 | $13.5 | $21.9 | +62% |
| 2026 YTD | $21.9 | $31.4 | +44% |
MD has the edge over HIMS on returns for 2026, with the stronger performance.